"More than ever, with Servier 2030, we are focused on innovation and positive social impact thanks to an improved profitability and bold choices." Takeda's Adcetris has become the first drug ...

It is the second of two IDH-targeting drugs that Servier acquired as part of its $1.8 billion takeover of Agios’ oncology business in 2021, which could rise to $2 billion if vorasidenib reaches ...

Servier’s decision to exit a Parkinson’s disease pact has triggered belt tightening at French biotech Oncodesign Precision Medicine. | Servier’s decision to exit a Parkinson’s disease pact has ...

MOMA Therapeutics, a clinical-stage biopharmaceutical company discovering and developing a new generation of precision ...

Discover March 2025’s top biotech deals, featuring major collaborations in small molecules, bispecific antibodies and protein ...

Building on successes in epitranscriptomics, Aqemia aims to develop novel small-molecule drugs against this emerging and promising class of therapeutic targets. In parallel with advancing RNA ...

This did not call into question the value of the assets, quite the contrary, as OPM finalized the phase 1 healthy volunteers of OPM-101, with very good results, and prepared the REVERT study, for ...

Drug screening is the process by which potential drugs are identified and optimized before selection of a candidate drug to progress to clinical trials. It can involve screening large libraries of ...